Evolution of HIV integrase resistance mutations

Current Opinion in Infectious Diseases

Volumn 26, Issue 1, 2013, Pages 43-49

  Quashie, Peter K ^a,b   Mesplède, Thibault ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b Faculty of Medicine   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

HIV 1; integrase strand transfer inhibitors; resistance mutations

Indexed keywords

COBICISTAT; DOLUTEGRAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; INTEGRASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR DISOPROXIL;

ANTIVIRAL RESISTANCE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

DNA MUTATIONAL ANALYSIS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION;

EID: 84871781846     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835ba81c     Document Type: Review

References (54)

1. Hirsch MS. Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis 1990; 161:845-857. (Pubitemid 20148313)
2. FDA notifications. FDA approves raltegravir for HIV-1 treatment-naive patients. AIDS Alert 2009; 24:106-107.
3. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, doubleblind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439-2448.
4. Katlama C, Murphy R. Dolutegravir for the treatment of HIV. Expert Opin Investig Drugs 2012; 21:523-530.
5. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-650. (Pubitemid 30070911)
6. Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. BMC Med 2012; 10:34-45.
7. Hare S, Vos AM, Clayton RF, et al. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010; 107:20057-20062.
8. Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011; 80:565-572.
9. The PyMOL Molecular Graphics System, Version 1.3. Schrö dinger, LLC.
10. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194 (Suppl. 1):S51-S58. (Pubitemid 44420873)
11. Bar-Magen T, Sloan RD, Donahue DA, et al. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol 2010; 84:9210-9216.
12. Blanco JL, Varghese V, Rhee SY, et al. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204-1214.
13. Dicker IB, Terry B, Lin Z, et al. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 2008; 283: 23599-23609.
14. GoethalsO, Clayton R, VanGinderen M, et al. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008; 82:10366-10374.
15. Goethals O, Van Ginderen M, Vos A, et al. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a secondgeneration HIV-1 integrase inhibitor. Antiviral Res 2011; 91:167-176.
16. Hazuda DJ. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz J Infect Dis 2010; 14:513-518.
17. Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011; 55:813-821.
18. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. AIDS 2011; 25:1175-1178.
19. Quashie PK, Mesplede T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the secondgeneration integrase strand transfer inhibitor dolutegravir. J Virol 2012; 86:2696-2705.
20. Van Wesenbeeck L, Rondelez E, Feyaerts M, et al. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob Agents Chemother 2011; 55:321-325.
21. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis 2006; 194 (Suppl. 1):S51-58. (Pubitemid 44420873)
22. Seki T, Kobayashi M, Wakasa-Morimoto C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. In: 17th CROI Conference on Retroviruses and Opportunistic Infections; February 27-March 2, 2010; San Francisco, CA; 2010.
23. Jones G, Ledford R, Yu F, et al. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). In: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA; 2007.
24. Fransen S, Gupta S, Danovich R, et al. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol 2009; 83:11440-11446.
25. Fransen S, Gupta S, Frantzell A, et al. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo. J Virol 2012; 86:7249-7255.
26. Codoner FM, Pou C, Thielen A, et al. Dynamic escape of preexisting raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88:281-286.
27. Armenia D, Vandenbroucke I, Fabeni L, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012; 205:557-567.
28. Winters MA, Lloyd RM Jr, Shafer RW, et al. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One 2012; 7:e40514.
29. Young B, Fransen S, Greenberg KS, et al. Transmission of integrase strandtransfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy. Antivir Ther 2011; 16:253-256.
30. Boyd SD, Maldarelli F, Sereti I, et al. Transmitted raltegravir resistance in an HIV-1 CRF-AG-infected patient. Antivir Ther 2011; 16:257-261.
31. Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther 2011; 16:137-140.
32. Fransen S, Karmochkine M, Huang W, et al. Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother 2009; 53:4522-4524.
33. Mesplede T, Quashie PK, Wainberg MA. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7:401-408.
34. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 2006; 57ss:619-627.
35. Seki T KM, Wakasa-Morimoto C, Yoshinaga T, et al. No impact of HIV integrase polymorphisms at position 101 and 124 on in vitro resistance isolation with dolutegravir (DTG, S/GSK1349572), a potent next generation HIV integrase inhibitor. In: 6th IAS Conference on HIV Pathogenesis Treatment and Prevention; 17-20 July 2011; Rome, Italy; 2011. Poster TUP092.
36. Bar-Magen T, Donahue DA, McDonough EI, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 2010; 24:2171-2179.
37. Margot NA, Hluhanich RM, Jones GS, et al. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 2012; 93:288-296.
38. Desimmie BA, Schrijvers R, Debyser Z. Elvitegravir: a once daily alternative to raltegravir. Lancet Infect Dis 2012; 12:3-5.
39. Goethals O, Vos A, Van Ginderen M, et al. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010; 402:338-346.
40. Jones G, Ledford R, Yu F, et al. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). In: 14th Conference on retroviruses and opportunistic infections; February 25-28, 2007; Los Angeles, CA; 2007.
41. Mbisa JL, Martin SA, Cane PA. Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist 2011; 4:65-76.
42. Van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12:111-118.
43. Boyd M. Dolutegravir-a promising antiretroviral in development. Lancet Infect Dis 2012; 12:90-91.
44. Malet I, Fourati S, Charpentier C, et al. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02-AG HIV-1 subtype. J Antimicrob Chemother 2011; 66:2827-2830.
45. Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011; 204:1811-1815.
46. Garrido C, Soriano V, Geretti AM, et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients-impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011; 90:164-167.
47. Underwood MR, Johns BA, Sato A, et al. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012; 61:297-301.
48. Hightower KE, Wang R, Deanda F, et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011; 55:4552-4559.
49. Brenner BG, Lowe M, Moisi D, et al. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol 2011; 83:751-759.
50. Fagard C, Colin C, Charpentier C, et al. Long-term efficacy and safety of raltegravir, etravirine, and darunavir/ritonavir in treatment-experienced patients: week 96 results from the ANRS 139 TRIO trial. J Acquir Immune Defic Syndr 2012; 59:489-493.
51. Elion R, Gathe J, Rashburn B, et al. The single-tablet regimen elvitegravir/cobicstat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; 'QUAD') maintains a high rate of virologic supression, and cobicstat (COBI) is an effective pharmacoenhancer through 48 weeks. In: 50th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 October 2010; Boston, MA; 2010.
52. Anonymous. Single-tablet Quad regimen achieves high rate of virologic suppression. AIDS Patient Care STDS 2010; 24:197.
53. Marchand C. The elvitegravirQuad pill: the first once-daily dual-target anti-HIV tablet. Expert Opin Investig Drugs 2012; 21:901-904.
54. Crunkhorn S. Trial watch: HIV integrase inhibitor-based regimen beats market leader. Nat Rev Drug Discov 2012; 11:664.